Ibogaine receives more political attention
In the United States, a new bill has been introduced to accelerate research into ibogaine. The so-called IBOGAINE Act builds upon the earlier presidential decision to encourage research into psychedelic treatments for serious mental illnesses. If the law passes, the U.S. Department of Justice will be instructed to investigate whether ibogaine can be moved from Schedule I to Schedule II, thereby making scientific research easier.
What is ibogaine?
Ibogaine is a psychoactive substance derived from the root bark of the African iboga plant. The substance has been studied for years due to its potential role in the treatment of addictions, including opioid and alcohol addiction. Although initial research results are promising, ibogaine remains a Schedule I substance in the United States. This means that, according to the federal government, the substance has no recognized medical application and carries a high risk of abuse.
More research, but also attention to safety
Proponents of the new law argue that a less strict classification can significantly accelerate scientific research. At the same time, researchers emphasize that ibogaine is not without risk. The substance can cause serious side effects, including cardiac arrhythmias. Therefore, experts believe that its use should take place exclusively under medical supervision and within controlled studies.
Ready to see how Snowflake works?
With the IBOGAINE Act, political attention to psychedelic medicine in the United States appears to be increasing further. Should the law be passed, it could be an important step toward more extensive research into ibogaine and the potential role of psychedelics within mental healthcare.
Source: psychedelicstoday.com en whitehouse.gov
